Insulet makes the Omnipod system, a wearable, tubeless insulin pump for people with diabetes. Unlike traditional tethered pumps, Omnipod uses disposable pods that stick to the body and are controlled wirelessly. The company sells primarily into the diabetes care market—patients, endocrinologists and payers—and has expanded automated insulin-delivery features paired with continuous glucose monitors.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 649.1 | — | 22.5 | -41.6% |
| Q3 2025 | 706.3 | — | 87.6 | 36.8% |
| Q4 2025 | 783.8 | — | 101.6 | 25.9% |
| Q1 2026 | 761.7 | — | 91.1 | 27.2% |
| Q2 2026 | 801.7 | 23.5% | 95 | 322.2% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Cognex Corporation (CGNX), PayPay Corporation (PAYP), Apogee Therapeutics, Inc. (APGE), Repligen Corporation (RGEN), Wintrust Financial Corporation (WTFC), Leonardo DRS, Inc. (DRS)